Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of turoctocog alfa pegol in previously treated severe haemophilia A
NL-OMON46773Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of octocog alfa in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Number of adverse events reported. Started Jun 2018; status: active, not recruiting.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON46773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46773.